# Add Glucokinase Activator to Target A1c

Study · id `cardio:ct-nct02405260` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02405260](<https://clinicaltrials.gov/study/NCT02405260>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02405260

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 190 participants.

## Technical summary

Registry record NCT02405260. Randomized; double masking; primary purpose treatment. Start 2015-03 (registry gives no type); primary completion 2016-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 190 participants (enrolled count; ClinicalTrials.gov record NCT02405260, source copy `cardio:ctgov-nct02405260-2017-02-10`, retrieved 2026-10-26)
- Start date: 2015-03 (registry gives no type) (ClinicalTrials.gov record NCT02405260, source copy `cardio:ctgov-nct02405260-2017-02-10`, retrieved 2026-10-26)
- Primary completion: 2016-07 (actual) (ClinicalTrials.gov record NCT02405260, source copy `cardio:ctgov-nct02405260-2017-02-10`, retrieved 2026-10-26)
- Completion: 2016-09 (actual) (ClinicalTrials.gov record NCT02405260, source copy `cardio:ctgov-nct02405260-2017-02-10`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02405260, source copy `cardio:ctgov-nct02405260-2017-02-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02405260-2017-02-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Add Glucokinase Activator to Target A1c
- Acronym: AGATA
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): TTP399 400 mg
- Intervention (Drug): TTP399 800 mg
- Intervention (Drug): Sitagliptin 100 mg
- Intervention (Drug): Placebo
- Lead sponsor: vTv Therapeutics
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: vTv Therapeutics (`cardio:org-vtv-therapeutics`)

## Provenance

Content hash: 9f4b1202b80f5b5506c287dc099ee69801031eb3ed6a7ce11701617d7fcd6f05
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
